Abbott Laboratories (ABT) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Abbott Laboratories  (NYSE: ABT)

Abbott Laboratories's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Abbott Laboratories in the third quarter 2026?
Abbott Laboratories achieved a return on average equity (ROE) of 9 % in its third quarter 2026, which is below Abbott Laboratories's average return on equity, which stands at 16.95%.

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 51 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 1189, from total ROE ranking in the second quarter 2026 at 1271.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Equity Change 0.7 % 1.84 % 7.41 % 10.17 % -
Y / Y Net Income Change -44.04 % -47.84 % -18.72 % -80.76 % -0.12 %
Net Income (TTM) in Millions 4,701 5,425 6,276 6,524 13,977
Return On Equity (TTM) 9 % 10.41 % 12.09 % 12.8 % 28.09 %
ABT's Total Ranking # 1189 # 1271 # 409 # 364 # 351
Equity (TTM) in Millions 51,623 51,762 52,701 52,771 51,264
Seq. Equity Change -0.27 % -1.78 % -0.13 % 2.94 % 0.86 %
Seq. Net Income Change -0.86 % -13.83 % -39.36 % 8.03 % -7.59 %

Back to ABT Management Effectiveness >> ABT's 5 Years Annual ROE >> Compare ABT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 52
Sector # 149
Overall # 1189

Return On Equity Statistics
High Average Low
32.19 %
16.95 %
1.5 %
(Dec 31 2024)   (Mar 31 2018)





ABT Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 52,771 47,901 38,827 36,905 36,024
Y / Y Equity Change 10.17 % 23.37 % 5.21 % 2.45 % 9.15 %
Net Income in Millions 6,524 13,402 5,723 6,933 7,071
Y / Y Net Income Change -51.32 % 134.18 % -17.45 % -1.95 % 57.31 %
Return On Equity 12.36 % 27.98 % 14.74 % 18.79 % 19.63 %

Back to ABT Management Effectiveness >> ABT's 5 Years Annual ROE >> Compare ABT ROE to its Competitors




Annual Roe Comment
In 2025 ROE decreased compared to the previous year to 12.36 %, due to deterioration of net income.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ABT's' Return on Equity at Yahoo Finance
ABT's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ABT's Competitors
Subscribers only: Roe for Abbott Laboratories's Suppliers
Subscribers only: Return On Equity for ABT's Customers




Companies with similar Return On Equity at Sep 30 2026, within Healthcare Sector ROE
Bioventus Inc   24.60 %
Encompass Health Corporation  24.08 %
Iradimed Corporation  23.90 %
Corcept Therapeutics Inc  22.88 %
Msa Safety Inc  21.79 %
Lantheus Holdings Inc   21.72 %
Iqvia Holdings Inc   21.40 %
Denali Therapeutics Inc   21.40 %
West Pharmaceutical Services Inc   21.08 %
Brightspring Health Services Inc   20.31 %
Healthcare Services Group Inc   20.22 %
Vertex Pharmaceuticals Inc  20.08 %
Ge Healthcare Technologies Inc   20.04 %
Neurocrine Biosciences Inc   19.74 %
Ani Pharmaceuticals Inc  19.70 %
Johnson and Johnson  19.55 %
Beone Medicines Ltd   18.21 %
Pediatrix Medical Group Inc   17.28 %
Kiniksa Pharmaceuticals International Plc  17.27 %
Krystal Biotech Inc   17.02 %
Intuitive Surgical Inc   16.99 %
Ensign Group Inc  16.62 %
Lemaitre Vascular Inc   15.81 %
Stryker Corp  15.61 %
Quest Diagnostics Inc  15.22 %
Regeneron Pharmaceuticals Inc   15.07 %
Bio rad Laboratories Inc   14.07 %
Boston Scientific Corporation  13.75 %
Inspire Medical Systems inc   12.49 %
Haemonetics Corporation  12.07 %

Date modified: 2026-11-10T11:44:57+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.